Stephen Webster

Stephen W.
Webster was the founder of Neuronyx, Inc., founded in 2000, where the title held was President & Chief Executive Officer from 2000 to 2006.
Current jobs include Director at Nuron Biotech, Inc.; Independent Director at NextCure, Inc. since 2019; Director at Imvax, Inc. since 2023; Director at Spark Therapeutics UK Ltd. since 2016; Independent Director at Cullinan Therapeutics, Inc. since 2020; and Independent Director at Eloxx Pharmaceuticals, Inc. starting in 2026.
Former jobs include Chairman at TCR² Therapeutics, Inc. from 2022 to 2023; Independent Director at HearUSA, Inc. from 2011 to 2012; Managing Director-Healthcare Investment Banking at Broadpoint.
Gleacher Securities; Director-Investment Banking Division at PaineWebber, Inc. in 2000; Managing Director-Investment Banking Division at Broadpoint Securities, Inc. from 2007 to 2008; Director at Life Sciences Pennsylvania; Independent Director at Viking Therapeutics, Inc. from 2014 to 2020; Independent Director at Cullinan Oncology LLC; Director at Triplet Therapeutics, Inc.; Independent Director at Nabriva Therapeutics Plc; Independent Director at Gritstone bio, Inc. from 2024 to 2025; Chief Financial Officer & Senior Vice President at Adolor Corp.
from 2010 to 2011; Chief Financial Officer & Senior Vice President at Optimer Pharmaceuticals LLC from 2012 to 2013; Member-Supervisory Board at Nabriva Therapeutics GmbH from 2016 to 2017; and Chief Financial & Accounting Officer at Spark Therapeutics, Inc. from 2014 to 2019.
Education includes an undergraduate degree from Dartmouth College conferred in 1983 and an MBA from The Wharton School of the University of Pennsylvania.